FINNENCE ▪ THE WIRE FILE
THE WIRE · № 84091
News■ Unclear/unknown
Cyrano Therapeutics Announces Presentation of Positive Phase 2 FLAVOR Data Demonstrating Statistically Significant Improvement in Smell Function with CYR-064 in Patients with Post-Viral Smell Loss
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Positive Phase 2 smell-loss data is for a private company, so no listed equity is directly affected.
Clinical data, but issuer is private
CATALYST TO WATCH
Phase 3 initiation or partnership
MAIN RISK
Small trial, unproven endpoint
FULL DISPATCH
Data selected for first oral presentation in the "Top 5 Clinical Science" track at the 72nd Annual Meeting of the American Rhinologic Society DELRAY BEACH, Fla., Oct. 16, 2026 /PRNewswire/ -- Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company developing novel...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
CTY IPO News - City Therapeutics prices upsized IPO at $18, the midpoint of the range2026-10-16 12:47 UTC
CTY IPO News - City Therapeutics prices upsized IPO at $18, the midpoint of the range2026-10-16 12:47 UTC
→CORRELATIONshares Healthcare
Health Care and Crude Led the Week While Tech Lost Its Grip2026-10-16 13:10 UTC
Health Care and Crude Led the Week While Tech Lost Its Grip2026-10-16 13:10 UTC
←CORRELATIONshares Healthcare
Phase 3 results posted: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma — Nektar Therapeutics2026-10-16 12:00 UTC
Phase 3 results posted: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma — Nektar Therapeutics2026-10-16 12:00 UTC
←CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin — Eli Lilly and Company2026-10-16 12:00 UTC
Phase 3 results posted: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin — Eli Lilly and Company2026-10-16 12:00 UTC
←CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis — Eli Lilly and Company2026-10-16 12:00 UTC
Phase 3 results posted: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis — Eli Lilly and Company2026-10-16 12:00 UTC
←CORRELATIONshares Healthcare
Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement2026-10-16 12:00 UTC
Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement2026-10-16 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.